Viking Therapeutics
VKTX
156 hedge funds and large institutions have $374M invested in Viking Therapeutics in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 43 reducing their positions, and 24 closing their positions.
58% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $12.3M
16% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.93% less ownership
Funds ownership: 63.51% → 62.59% (-0.93%)
5% less funds holding
Funds holding: 164 → 156 (-8)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
18% less capital invested
Capital invested by funds: $454M → $374M (-$80.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$20.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.04M |
| 3 |
Citigroup
New York
|
+$4.09M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.49M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$17.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.86M |
| 3 |
CCI
Columbus Circle Investors
|
-$3.57M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$3.09M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3M |
VKTX Hedge Fund Activity: Q2 2019 in Review
156 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2019, worth a combined $374M — down 18% from $454M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of VKTX and 21 opened new positions — a net loss of 3 holders — while 43 trimmed existing stakes and 50 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $20.1M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $17.5M sold.
- 156 institutional investors held Viking Therapeutics (VKTX) as of Q2 2019, down from 164 in Q1 2019.
- Funds reported $374M of Viking Therapeutics stock for Q2 2019, down 18% quarter-over-quarter.
- 21 funds opened new Viking Therapeutics positions in Q2 2019 and 24 closed out, a net change of -3 holders.
- The largest Viking Therapeutics buyer in Q2 2019 was ArrowMark Colorado Holdings, an estimated $20.1M added.
- The largest Viking Therapeutics seller in Q2 2019 was Eventide Asset Management, an estimated $17.5M sold.
Based on aggregated 13F filings for Q2 2019.